Belite Bio To Present Tinlarebant Data At Euretina
(RTTNews) - Tuesday, Belite Bio (BLTE) said it will present data from its retinal disease programs at two upcoming medical conferences in Vienna, including topline Phase 3 DRAGON study results for tinlarebant in adolescent Stargardt disease.
Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A-derived bisretinoids linked to retinal damage in Stargardt disease.
The DRAGON study met its primary endpoint, and Belite Bio's FDA application for tinlarebant in Stargardt disease received priority review in August 2026. The FDA has set a PDUFA date of February 12, 2027.
Currently, BLTE is trading at $165.45, down 0.29%.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.